What side effects are associated with this type of intervention?

Common treatments for Post-COVID Syndrome, particularly those involving regenerative and immunomodulatory therapies like Hematopoietic Progenitor Cells from human Umbilical Cord Blood, may include side effects such as infusion reactions, fever, chills, and allergic reactions. Other potential side effects can involve transient changes in blood counts, mild to moderate gastrointestinal symptoms, and, in rare cases, more severe immune responses. It is important for patients to discuss these potential risks with their healthcare provider to make an informed decision.

What prior FDA approvals exist?

As of now, there are no specific FDA-approved treatments for Post-COVID Syndrome that are directly analogous to RegeneCyte, which uses Hematopoietic Progenitor Cells from human Umbilical Cord Blood for its regenerative and immunomodulatory effects. Current management of Post-COVID Syndrome primarily focuses on symptomatic relief and supportive care, with ongoing research and clinical trials exploring various therapeutic options, including regenerative medicine approaches.

What other types of research exist?

Promising alternatives to RegeneCyte for Post-COVID Syndrome patients in 2024 include mesenchymal stem cell (MSC) therapy, induced pluripotent stem cell (iPSC) therapy, and thrombopoietin receptor agonists such as romiplostim and eltrombopag. These therapies have shown potential in regenerative medicine and immunomodulation, which could be beneficial for Post-COVID Syndrome.

← Back to Search

Stem Cell Therapy

RegeneCyte for Post-COVID Syndrome

Phase 2

Waitlist Available

Research Sponsored by StemCyte International, Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

With post-COVID syndrome

Be older than 18 years old

Must not have

Neurological disorders prior to COVID-19 diagnosis

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 48

Summary

This trial is testing a treatment using stem cells from umbilical cord blood in patients who have ongoing symptoms after recovering from COVID-19. The stem cells may help the body heal by repairing damaged tissues and reducing inflammation. The study will compare the effects of this treatment to another group. These stem cells have shown promise in reducing mortality and improving lung symptoms in COVID-19 patients.

Who is the study for?

This trial is for adults over 18 who have post-COVID syndrome and can commit to the study's requirements. They must test negative for COVID-19 before joining. People with neurological issues predating COVID, recent vaccinations, participation in other studies, immune diseases, terminal illnesses or pregnancy/breastfeeding cannot join.

What is being tested?

The trial is testing RegeneCyte (a human umbilical cord blood treatment) against a placebo to see if it helps patients with post-COVID syndrome. Participants will receive either the real treatment or a placebo without knowing which one they are getting.

What are the potential side effects?

Potential side effects of RegeneCyte are not specified here but could include reactions at the infusion site, allergic responses or other unforeseen complications related to stem cell therapies.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am experiencing long-term effects after recovering from COVID-19.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I had a neurological disorder before getting COVID-19.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 48

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 48

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 48 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Treatment-emergent adverse events (TEAEs)

Secondary study objectives

The change of efficacy

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: RegeneCyteExperimental Treatment1 Intervention

HPC, Cord Blood

Group II: PlaceboPlacebo Group1 Intervention

Normal Saline

0 / 2Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for Post-COVID Syndrome, such as those involving Hematopoietic Progenitor Cells (HPC) from human umbilical cord blood, work primarily through regenerative and immunomodulatory mechanisms. These treatments aim to repair damaged tissues and modulate the immune response to reduce chronic inflammation. For Post-COVID Syndrome patients, this is crucial as it addresses the lingering symptoms caused by persistent inflammation and tissue damage, thereby improving overall recovery and quality of life.

A Novel Method for the Production of an Autologous Anti-Inflammatory and Anti-Catabolic Product (Cytorich) from Human Blood: A Prospective Treatment for the COVID-19-Induced Cytokine Storm.Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy.Stem cell-derived biofactors fight against coronavirus infection.